Stocks List: Jacobs Engineering Group Inc, Western Potash Corp, DryShips Inc, Onyx Pharmaceuticals

Dallas, TX -- (SBWIRE) -- 03/11/2013 -- Marketbuzzreport.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Jacobs Engineering Group Inc NYSE:JEC) shares jumped 2.80% and closed at $51.82. The company last week announced that it has been selected by the Shell Company of Australia Ltd. for its Clyde Terminal Conversion Project in Sydney, Australia. Officials did not disclose the contract value, but noted that the work is being performed from Jacobs' Australian operations in Melbourne and Sydney.

How Should Investors Trade JEC After The Recent Price movement? Find out Here

Western Potash Corp. (TSE:WPX) shares gained 5.49% and closed at $0.480. The company, on Feb. 28, announced its unaudited operating and financial results for the fourth quarter and the year ended Dec. 31, 2012. The company reported an unaudited net loss of $223 million for full-year 2012, or a loss of $1.12 per share on a fully-diluted basis, compared with a net loss of $302 million, or a loss of $1.53 per share, in 2011. The net loss from continuing operations was $245 million in 2012 vs. $160 million for full-year 2011.

Is WPX a Strong Buying Opportunity After The Recent Slump? Find out Here

DryShips Inc. (NASDAQ:DRYS) shares increased 2.62% to $1.96. The company, on Mar. 7, reported a fourth quarter loss of $129.8 million, or 34 cents a share, compared with a year-earlier loss of $6.2 million, or two cents a share. Adjusted loss was 15 cents a share in the latest period. Revenue fell 14% to $282.9 million. Analysts were expecting a per-share loss of 11 cents a share on revenue of $294 million.

Is DRYS a Buy After The Latest Price Action? Find Out Here

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) shares climbed 2.59% and closed at $85.65. ONXX’s stock ONXX’s stock was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research note issued on Mar. 8. They currently have a $88.00 price target on the stock.

Additionally, Bayer HealthCare and Onyx Pharmaceuticals, on Feb. 25, announced that the U.S. Food and Drug Administration (FDA) approved Bayer's Stivarga (regorafenib) tablets to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.

Is ONXX a Buy After The Latest Price Action? Find Out Here

About Marketbuzzreport.com
Marketbuzzreport.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Marketbuzzreport.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.marketbuzzreport.com

Disclaimer
The assembled information disseminated by Marketbuzzreport.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Marketbuzzreport.com does expect that investors will buy and sell securities based on information assembled and presented in Marketbuzzreport.com. PLEASE always do your own due diligence, and consult your financial advisor.